Status:
COMPLETED
Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC
Lead Sponsor:
University of Birmingham
Collaborating Sponsors:
Efficacy and Mechanism Evaluation (EME) Programme
Conditions:
Merkel Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC
Detailed Description
A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC with an observational study for patients ineligible for the r...
Eligibility Criteria
Inclusion
- General Inclusion Criteria for All Patients:
- Patients newly diagnosed with histologically-proven MCC (either primary and/or regional nodal disease)
- Completion of clinical and radiological staging investigations, including CT imaging (or other modality) of regional nodal basin(s) and major viscera (and SLNB if clinically appropriate) to identify regional and distant metastases
- No confirmed distant metastases beyond the regional nodal basin (i.e. not stage IV disease)
- Suitable for radical treatment to achieve disease control
- Able to give valid informed consent
- Consent for collection of data and tissue samples and follow up
- Life expectancy six months or greater in relation to general fitness and co-morbidities
- Additional Inclusion Criteria for Rational Compare:
- Patients newly diagnosed with histologically-proven primary MCC
- In the opinion of the SSMDT, the primary MCC can be encompassed both within a wide surgical margin and within a radiotherapy field, and the SSMDT is in equipoise regarding WLE or radiotherapy as first treatment
- A minimum margin of 1 cm surrounding the MCC achievable by either radiotherapy or surgery
- Consent for randomisation into Rational Compare
Exclusion
- The primary MCC has already been treated radically with WLE (surgical margins \>10 mm) or radiotherapy
- Intended use of regional or systemic chemotherapy for MCC (including molecularly targeted agents and immunotherapy)
Key Trial Info
Start Date :
March 19 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 13 2023
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT05253144
Start Date
March 19 2016
End Date
April 13 2023
Last Update
May 8 2024
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Birmingham NHS Foundation Trust
Birmingham, United Kingdom
2
North Bristol NHS Trust
Bristol, United Kingdom
3
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
4
NHS Tayside
Dundee, United Kingdom